ES2791338T3 - Célula - Google Patents

Célula Download PDF

Info

Publication number
ES2791338T3
ES2791338T3 ES16726416T ES16726416T ES2791338T3 ES 2791338 T3 ES2791338 T3 ES 2791338T3 ES 16726416 T ES16726416 T ES 16726416T ES 16726416 T ES16726416 T ES 16726416T ES 2791338 T3 ES2791338 T3 ES 2791338T3
Authority
ES
Spain
Prior art keywords
domain
cells
cell
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16726416T
Other languages
English (en)
Spanish (es)
Inventor
Martin Pule
Shaun Cordoba
Simon Thomas
Khai Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of ES2791338T3 publication Critical patent/ES2791338T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
ES16726416T 2015-06-01 2016-05-31 Célula Active ES2791338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1509413.9A GB201509413D0 (en) 2015-06-01 2015-06-01 Fusion protein
PCT/GB2016/051576 WO2016193696A1 (en) 2015-06-01 2016-05-31 Cell

Publications (1)

Publication Number Publication Date
ES2791338T3 true ES2791338T3 (es) 2020-11-03

Family

ID=53677545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16726416T Active ES2791338T3 (es) 2015-06-01 2016-05-31 Célula

Country Status (20)

Country Link
US (2) US11345734B2 (enExample)
EP (2) EP3730609A1 (enExample)
JP (4) JP6833727B2 (enExample)
KR (1) KR102275460B1 (enExample)
CN (1) CN107667170B (enExample)
AU (1) AU2016272457B2 (enExample)
BR (1) BR112017023190A2 (enExample)
CA (1) CA2986956C (enExample)
CL (1) CL2017003057A1 (enExample)
DK (1) DK3303568T3 (enExample)
ES (1) ES2791338T3 (enExample)
GB (1) GB201509413D0 (enExample)
HU (1) HUE050132T2 (enExample)
IL (1) IL255594B (enExample)
MX (1) MX383118B (enExample)
PL (1) PL3303568T3 (enExample)
PT (1) PT3303568T (enExample)
RU (1) RU2729158C2 (enExample)
WO (1) WO2016193696A1 (enExample)
ZA (1) ZA201707334B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
KR20240132100A (ko) 2015-07-28 2024-09-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
EA201891614A1 (ru) * 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Химерные белки и способы иммунотерапии
NZ743983A (en) * 2016-01-11 2025-08-29 Univ Leland Stanford Junior Chimeric proteins and methods of regulating gene expression
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201621889D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Cell
US20230159619A1 (en) * 2017-02-23 2023-05-25 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity
US20200048359A1 (en) * 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018211244A1 (en) * 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
EP3687575A4 (en) * 2017-09-29 2021-06-30 National Health Research Institutes METHODS AND COMPOSITIONS FOR INCREASING SURVIVAL AND FUNCTIONALITY OF ANTITUMOR AND ANTIVIRUS T CELLS
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
US20210189367A1 (en) * 2017-12-11 2021-06-24 Senti Biosciences, Inc. Inducible Cell Receptors for Cell-Based Therapeutics
EP3810753A1 (en) * 2018-06-19 2021-04-28 Autolus Limited Cell
CN109294982B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rff2细胞
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019392687A1 (en) * 2018-12-06 2021-07-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
ES3051182T3 (en) 2019-01-23 2025-12-26 Miltenyi Biotec Bv & Co Kg A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2020190771A1 (en) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
US20230085318A1 (en) * 2019-05-07 2023-03-16 Modernatx, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof
CN112279922B (zh) * 2019-07-22 2023-07-28 南京助天中科科技发展有限公司 一种吞噬细胞嵌合抗原受体及其应用
GB2605276B (en) 2019-09-03 2024-08-07 Myeloid Therapeutics Inc Methods and compositions for genomic integration
US20220401537A1 (en) * 2019-09-16 2022-12-22 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
IL292387B2 (en) * 2019-10-23 2025-08-01 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Chimeric polypeptide for regulating immune cells
US20220389075A1 (en) * 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
IL293716A (en) 2019-12-11 2022-08-01 A2 Biotherapeutics Inc Lilrb1-based chimeric antigen receptor
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
EP3915578A1 (en) 2020-05-28 2021-12-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
CA3184807A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
KR102859548B1 (ko) 2020-08-20 2025-09-12 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
US20250019740A1 (en) * 2020-10-26 2025-01-16 Board Of Regents, The University Of Texas System Mutant proteases and uses thereof
MX2023005201A (es) 2020-11-04 2023-06-28 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
US20230405047A1 (en) 2020-11-09 2023-12-21 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
CN114807042B (zh) * 2021-01-22 2024-09-03 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
GB2623191A (en) 2021-03-17 2024-04-10 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
JP2024518100A (ja) 2021-05-11 2024-04-24 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
JP2023008482A (ja) 2021-07-06 2023-01-19 日本たばこ産業株式会社 たばこ製品の香味料担持構成部材及びこの製造方法
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
CN118574636A (zh) * 2021-11-04 2024-08-30 丹娜-法伯癌症研究院 开发可诱导簇嵌合抗原受体(ccar)构建体
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN119331105B (zh) * 2024-09-03 2025-10-28 中国人民解放军空军军医大学 靶向多种免疫检查点的通用多肽-protac及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
CA2223402C (en) * 1995-06-07 2012-07-31 University Of Pennsylvania Methods of inhibiting phagocytosis
WO1997031113A1 (en) * 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. Cell-based assay
WO2000063374A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic transmembrane components
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
MX386060B (es) * 2013-03-15 2025-03-18 Memorial Sloan Kettering Cancer Center Composiciones y usos para inmunoterapia.
ES2832586T3 (es) * 2013-11-21 2021-06-10 Autolus Ltd Célula
ES2927366T3 (es) * 2014-10-09 2022-11-04 Univ Yamaguchi Vector de expresión de CAR y células T que expresan CAR
GB201620070D0 (en) 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method

Also Published As

Publication number Publication date
JP6833727B2 (ja) 2021-02-24
HK1246825A1 (en) 2018-09-14
CN107667170B (zh) 2021-09-03
WO2016193696A1 (en) 2016-12-08
CL2017003057A1 (es) 2018-03-16
DK3303568T3 (da) 2020-07-06
GB201509413D0 (en) 2015-07-15
KR20180012762A (ko) 2018-02-06
JP2022066380A (ja) 2022-04-28
US20220267404A1 (en) 2022-08-25
MX2017014630A (es) 2018-06-06
CN107667170A (zh) 2018-02-06
BR112017023190A2 (pt) 2018-07-17
RU2017145074A3 (enExample) 2019-07-17
IL255594B (en) 2020-11-30
RU2729158C2 (ru) 2020-08-04
CA2986956C (en) 2022-03-22
CA2986956A1 (en) 2016-12-08
JP2018517410A (ja) 2018-07-05
KR102275460B1 (ko) 2021-07-14
ZA201707334B (en) 2020-02-26
JP2024149818A (ja) 2024-10-18
US11345734B2 (en) 2022-05-31
EP3303568A1 (en) 2018-04-11
JP2020115898A (ja) 2020-08-06
MX383118B (es) 2025-03-13
IL255594A (en) 2018-01-31
RU2017145074A (ru) 2019-07-09
AU2016272457A1 (en) 2017-12-14
EP3730609A1 (en) 2020-10-28
PT3303568T (pt) 2020-06-08
EP3303568B1 (en) 2020-05-06
HUE050132T2 (hu) 2020-11-30
US20190023761A1 (en) 2019-01-24
PL3303568T3 (pl) 2020-11-02
AU2016272457B2 (en) 2020-12-10
NZ737662A (en) 2021-10-29

Similar Documents

Publication Publication Date Title
ES2791338T3 (es) Célula
JP7602475B2 (ja) 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
ES2905377T3 (es) Célula
EP3071222B1 (en) Cell
ES3040594T3 (en) Cell
US20200338124A1 (en) Cell
US20190309046A1 (en) Signal transduction modifying protein
BR122025000772A2 (pt) Célula
HK1246825B (en) Cell
NZ737662B2 (en) Cell
HK1223553B (en) Cell